Crinetics to Present Two-Year PALSONIFY Efficacy and Safety Data, Launches Patient Advocacy Program
CRNX sits 24% above its 52-week low of $25.83.
Summary
Crinetics Pharmaceuticals announced it will present two-year pooled efficacy and safety data for its key drug PALSONIFY, alongside real-world and combination data. This follows the European Commission approval of PALSONIFY in April and strong Q1 2026 product revenue growth. The new long-term and real-world data can further strengthen PALSONIFY's market position and influence physician adoption. Additionally, the company launched a patient advocacy program for acromegaly.
At the time of this announcement, CRNX was trading at $31.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $25.83 to $57.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.